Measles in Adults: Who Is Actually Protected, Who Needs an MMR Booster and How Immunity Is Checked

A colleague of mine, a nurse in her fifties, recently spent twenty minutes on hold with her mother trying to establish whether she had received one measles shot or two in 1974. Her mother remembered the doctor’s office wallpaper. She did not remember the needle. That phone call is being repeated in thousands of households right now, and for a concrete reason: as of early 2026, the United States has just come through its largest measles year since 1992, Canada has lost its measles-elimination status, and outbreaks have reached adults who assumed the disease belonged to history books.

Measles in adults is a different conversation from measles in toddlers. The questions are about paperwork, birth years, a vaccine that was quietly withdrawn in the 1960s, and a blood test that sounds simpler than it is. Search interest in “am I immune to measles” has climbed alongside the case counts, and much of what people find is either a pediatric leaflet or a rumor.

This piece is the adult version: who is actually protected, who genuinely needs another dose, how immunity is checked, and what the evidence behind each answer looks like.

What changed recently: why measles in adults is trending

Three developments pushed this topic from public-health journals into everyday search. The first is arithmetic. CDC’s surveillance page recorded more than 1,500 confirmed measles cases in the United States during 2025, the highest annual figure since 1992 and more than five times the total for 2024. Roughly nine in ten of those cases occurred in people who were unvaccinated or whose status was unknown, and about one in eight required hospital care. Children carried the heaviest burden, but adults accounted for a substantial share of cases and of hospital admissions.

The second development came in November 2025, when the Pan American Health Organization confirmed that Canada had lost its measles-elimination status after more than twelve months of continuous transmission traced to a single outbreak. Elimination status is a formal designation meaning a country has interrupted homegrown spread for at least a year; losing it is a bureaucratic sentence with real meaning. It signals that enough unprotected people exist for the virus to keep finding a path. The United States, which has held the designation since 2000, entered 2026 with its own status under review for the same reason.

The third development is quieter: a wave of viral posts claiming that adult immunity “wears off,” that everyone needs a booster, or that a vitamin can substitute for vaccination. None of these claims reflects current CDC, WHO or NHS guidance, and each is addressed later in this article.

The guidance itself has not changed. CDC’s adult recommendations, WHO’s fact sheet and the NHS vaccination pages say what they said five years ago. What changed is the reason to read them. The virus is once again circulating in places where an adult with a fuzzy vaccination history might sit next to it on a plane, in a waiting room or at a wedding.

Who is actually protected from measles? The four kinds of evidence

Public-health agencies do not ask whether you “feel” immune. They ask for one of four specific things, and CDC lists them explicitly as acceptable presumptive evidence of immunity for adults.

• Written documentation of vaccination. For most adults this means one dose of a live measles-containing vaccine given on or after the first birthday. For adults in higher-risk settings, it means two doses separated by at least 28 days. The MMR vaccine, a combined shot protecting against measles, mumps and rubella, has been the standard live vaccine since 1971.
• Laboratory evidence of immunity. A blood test showing measles IgG antibodies. IgG is the long-lived antibody class that remains after infection or vaccination and is the marker labs use to indicate protection.
• Laboratory confirmation of past measles disease. Not a parent’s recollection of a childhood rash, but a documented positive test at the time of illness.
• Birth before 1957. People born before this year in the United States are considered immune because measles circulated so widely that nearly everyone was infected in childhood.

Notice what is missing from the list. A memory of “having all my shots” does not count. Neither does a childhood illness that a relative believes was measles, since rubella, roseola and several other viral rashes were routinely confused with it. Health-care employers and universities follow this list closely, which is why a new job or graduate program is often the moment an adult discovers the paperwork gap.

The list also explains why the practical question is rarely “am I protected” and more often “can I prove it.” An adult who received two MMR doses in 1985 is very likely protected. If the records were lost in a house move, that adult has the same options as someone never vaccinated: get a dose, or get tested first. Guidance treats both as reasonable, and the sections that follow explain the trade-offs.

Do adults need an MMR booster?

The short answer from CDC is no, not for most people. Two documented doses of MMR are considered to provide lifelong protection against measles, and a third dose is not recommended for adults simply because time has passed. The word “booster” is doing a lot of work in viral posts, so it helps to separate two different situations.

The first is an adult who has never completed the series. Someone born in 1957 or later with no evidence of immunity should receive at least one dose. If that person works in health care, travels internationally, attends a college or other post-secondary institution, or lives in an area where public-health authorities have advised it during an outbreak, two doses are recommended. That second dose is not a booster in the sense of topping up faded immunity; it is completing a series. About 93 percent of people respond to one dose and about 97 percent to two, so the second dose mainly catches the small minority who did not respond the first time.

The second situation is an adult who did complete two doses and is now wondering whether protection has expired. Here the evidence is reassuring. Long-term follow-up studies show that measurable antibodies persist for decades, and the small annual decline in antibody levels has not translated into meaningful numbers of measles cases among fully vaccinated adults. During recent US outbreaks, the overwhelming majority of cases occurred in unvaccinated people, not in vaccinated adults with waning immunity.

Two narrow exceptions exist. People vaccinated between 1963 and 1967 may have received an inactivated vaccine that did not produce durable protection; they are advised to receive live vaccine, and a separate section below explains why. And during a specific mumps outbreak, public-health authorities have sometimes recommended an additional MMR dose for the mumps component, a decision made locally rather than as a general rule.

The MMR booster question, then, usually resolves into a documents question. Find the records; if you have two doses, you are done. If you cannot find them, the next section covers how immunity is checked.

Am I immune to measles? How a titer test works and what it misses

A titer is a blood test that measures the concentration of a specific antibody. For measles, laboratories look for IgG antibodies against the virus and report the result as positive, negative or equivocal, the last meaning the level falls in a gray zone that the test cannot confidently call either way.

A positive measles IgG result is accepted by CDC as evidence of immunity. That is the good news, and it is why titers are common in occupational-health screening for hospital staff, where documentation is mandatory.

The limitations are less widely appreciated. A negative or equivocal titer does not necessarily mean a person is unprotected. Vaccinated people can have antibody levels that drift below the laboratory threshold while retaining immune memory, the ability of specialized cells to recognize the virus and mount a rapid response on re-exposure. This is why CDC guidance says that a person with documented two-dose vaccination does not need a titer and should not be considered susceptible on the basis of a low result. Testing someone with good records can create confusion rather than clarity.

For an adult with no records, testing has a different logic. If the result is positive, no vaccine is needed and the question is closed. If the result is negative or equivocal, the recommendation is to receive MMR, and there is no need to repeat the test afterward. Alternatively, an adult with no records can skip testing entirely and simply receive the vaccine. Giving MMR to someone who is already immune carries no added risk, since existing antibodies neutralize the vaccine virus, so the decision comes down to convenience, time and whether a blood draw is easier than an injection.

Timing matters when exposure is in play. A titer takes days to return; a vaccine given within 72 hours of exposure may prevent disease. In an outbreak, clinicians usually vaccinate first and ask questions later. Whichever route an adult takes, the interpretation belongs to the ordering clinician, who can weigh the result alongside age, history and current risk.

Born before 1957: why one year decides so much

The year 1957 appears in CDC guidance because of epidemiology rather than a birthday cutoff for the vaccine. Before the first measles vaccine was licensed in 1963, the virus infected essentially every child. Serologic surveys from that era found that well over 95 percent of adults carried measles antibodies, acquired the hard way. Someone born in 1956 would have been seven years old when vaccination began and would almost certainly have caught measles before then. The same is not true for someone born in 1960, who might have been vaccinated, might have caught wild measles, or might have missed both.

Natural infection produces durable immunity, and studies following people infected in the pre-vaccine era have found antibodies persisting for a lifetime. That is why CDC considers birth before 1957 acceptable evidence of immunity without a blood test or a vaccine record.

Two caveats sit alongside this rule. First, the assumption is statistical, not individual. A small number of people born before 1957 did escape childhood measles, and for that reason CDC advises that health-care facilities should consider vaccinating unvaccinated personnel born before 1957 who lack laboratory evidence of immunity, particularly during outbreaks. Outside health care, an adult in this age group who wants certainty can request a titer, and if it is negative, vaccination is an option to discuss.

Second, the rule is country-specific. The NHS does not use a birth-year cutoff; its guidance is that anyone who has not had two doses of MMR can ask their GP surgery for a catch-up, regardless of age. The UK’s vaccine program and outbreak history differ enough from the American one that the agencies drew the lines differently. An adult who grew up abroad should not assume the US cutoff applies to their childhood.

For an American in their late sixties or older, the practical takeaway is simple: you are presumed immune, a titer is not required, and the main reason to revisit the question is a job in health care or a personal desire for documentation.

Vaccinated between 1963 and 1967? The killed-vaccine gap

Here is a detail that catches many adults in their late fifties and early sixties by surprise. Two types of measles vaccine were licensed in 1963. One was a live attenuated vaccine, meaning a weakened virus that replicates enough to train the immune system without causing disease. The other was an inactivated, or killed, vaccine that contained no live virus. The killed version was used in the United States from 1963 until 1967, when it was withdrawn.

It was withdrawn for two reasons. Protection turned out to be short-lived, with antibodies fading within a few years. Worse, some recipients who later encountered wild measles developed an unusual, severe illness called atypical measles, with high fever, pneumonia and a rash that began on the extremities rather than the face. Roughly 600,000 to 900,000 people received the killed vaccine during those years.

CDC’s current advice is that adults who were vaccinated between 1963 and 1967 with the inactivated vaccine, or with a vaccine of unknown type, should be revaccinated with live MMR. Two doses are recommended for those in higher-risk groups such as health-care workers and international travelers. The inactivated vaccine does not count toward the two-dose series.

The catch, of course, is that almost nobody knows which type they received. Vaccination cards from the mid-1960s rarely specify, and many people have no card at all. The guidance handles this pragmatically: if the type is unknown and the dose was given in that window, treat it as if it were the killed vaccine and offer live MMR. The alternative is a titer, which will be positive in most people because many recipients of killed vaccine also received live vaccine later or caught measles naturally.

A related wrinkle applies to anyone vaccinated before their first birthday during the same era. Antibodies passed from mother to infant can neutralize a live vaccine given too early, so doses administered before 12 months of age are not counted as valid. Adults in this cohort who want clarity should raise the question with their clinician rather than assume.

Measles vaccine for adults: who needs what, at a glance

The rules above interact in ways that are easier to see laid out than described. The table summarizes CDC’s adult measles vaccination guidance; the NHS approach for UK residents is simpler, since it invites any adult without two documented MMR doses to catch up regardless of birth year. Individual circumstances such as pregnancy, immune-suppressing conditions or recent blood-product transfusions can change the answer, so the table is a map rather than a prescription.

Your situation	Considered immune?	What CDC guidance recommends
Born before 1957 (US)	Yes, presumptively	No vaccine or test needed; health-care employers may ask for a titer or a dose
Born 1957 or later, two documented MMR doses	Yes	Nothing further; no titer, no booster
Born 1957 or later, one documented dose, ordinary risk	Yes	One dose meets the adult standard
One documented dose, health-care worker, international traveler or college student	Not fully	A second dose at least 28 days after the first
Born 1957 or later, no records	Unknown	Either a titer, then MMR if negative or equivocal, or MMR without testing
Vaccinated 1963–1967 with killed or unknown-type vaccine	Not reliably	Revaccinate with live MMR; two doses if in a higher-risk group
Positive measles IgG on a blood test	Yes	Nothing further
Laboratory-confirmed past measles infection	Yes	Nothing further
Pregnant, or planning pregnancy within a month	Depends on records	MMR is not given during pregnancy; discuss timing with the clinician
Severely weakened immune system	Depends on records	Live vaccines are generally avoided; the specialist decides

Two patterns stand out. First, the vaccine question for adults is almost always a records question; the medical advice hinges on what can be documented. Second, the higher-risk categories are defined by exposure, not by frailty. A healthy 30-year-old flying to Europe for a wedding is in a higher-risk category than a healthy 30-year-old who stays home, because the virus is more likely to be met abroad. The measles vaccine for adults follows the virus, which is exactly how a prevention strategy should behave.

What happens if an adult gets measles?

Adults tend to get sicker. CDC identifies adults over 20, infants under 5, pregnant women and people with weakened immune systems as the groups most likely to develop complications. Measles is not a mild rash that adults simply shake off; it is a systemic viral infection that suppresses the immune system while it runs its course.

The common complications are the ones that fill hospital beds. Diarrhea affects roughly one in ten people with measles. Ear infections occur in about one in ten children and can cause permanent hearing loss. Pneumonia, the leading cause of measles death, develops in about one in twenty children and is more frequent in adults. Encephalitis, inflammation of the brain, occurs in roughly one in 1,000 cases and can leave lasting neurological damage. Death occurs in about one to three of every 1,000 people infected, a figure drawn from US surveillance, not from low-income settings. Among unvaccinated people, roughly one in five will be hospitalized.

Two consequences are less familiar. Immune amnesia is the term for measles’ ability to wipe out a portion of the body’s existing antibody memory, leaving a person more vulnerable to other infections for months or even years afterward. Observational studies following children after measles outbreaks have documented this effect, and there is no reason to think adults are spared. Subacute sclerosing panencephalitis, or SSPE, is a rare fatal brain disease that can appear seven to ten years after measles infection; it is very uncommon but has no treatment.

Pregnancy adds another layer. Measles during pregnancy is associated with higher rates of miscarriage, premature birth and low birth weight. It does not cause the specific birth defects associated with rubella, a distinction worth knowing because the two are often confused.

There is no antiviral medicine for measles. Care is supportive: fluids, rest, fever management and treatment of complications as they arise. For adults, the strongest reason to sort out immunity before exposure is that once measles begins, medicine can only manage what follows.

Symptoms of measles in adults and what the rash actually looks like

Measles arrives in stages, and the first stage looks like nothing special. Seven to fourteen days after exposure, a person develops fever, often climbing above 104°F, along with cough, runny nose and red, watery eyes. Clinicians call these the “three Cs”: cough, coryza and conjunctivitis. Coryza is the medical term for inflammation of the nasal lining, the ordinary runny nose. At this point measles is indistinguishable from a bad cold or flu, and it is already contagious.

Two to three days into that illness, small white spots may appear inside the mouth on the inner cheeks. These are Koplik spots, named for the pediatrician who described them, and they are close to unique to measles. They are easy to miss and fade quickly.

Three to five days after symptoms begin, the rash appears. It starts as flat red spots at the hairline and on the face, then spreads downward over the neck, trunk, arms, legs and feet over about three days. Small raised bumps often sit on top of the flat spots, and as the rash descends the spots may merge into larger blotches. The fever typically spikes as the rash emerges. The rash fades in the same order it appeared, sometimes leaving brownish staining and fine peeling.

On adults, the rash follows the same map. On darker skin, it may appear purple, dark brown or barely different from surrounding skin, and it can be easier to feel as slight roughness than to see. NHS guidance specifically notes that the rash may be harder to spot on brown and black skin, which has led to delayed recognition in adults.

What distinguishes adult measles clinically is intensity rather than pattern. Adults report more severe fatigue, higher and longer fevers, and more prominent eye symptoms, including light sensitivity. Because most adults and many clinicians have never seen a case, the illness is often first mistaken for influenza, a drug reaction or scarlet fever. The combination of high fever, cough, red eyes and a rash that begins on the face and moves down is the pattern worth recognizing.

When are you contagious after being exposed to measles?

Measles is the most contagious disease known to medicine, and the timeline explains why it spreads before anyone realizes what it is. The incubation period, the gap between exposure and first symptoms, runs from seven to fourteen days, though it can stretch to 21. During most of that window the infected person feels well and is not yet contagious.

Infectiousness begins about four days before the rash appears, which is roughly when the fever and cough start. It continues until about four days after the rash appears. That gives an eight-to-nine-day window, and the first half of it falls during the stage that looks like an ordinary cold. An adult who goes to work, attends a concert or flies home during those days can seed an outbreak without a single visible spot.

The mechanics of spread are unforgiving. The virus travels in respiratory droplets and, unlike most respiratory viruses, remains suspended in the air and infectious for up to two hours after an infected person has left the room. Roughly 90 percent of unprotected people who share air with an infectious case will become infected. Epidemiologists express this with a number called R0, the average number of people one case infects in a fully susceptible population; for measles it is estimated at 12 to 18, compared with roughly 1.3 for seasonal influenza.

Those figures drive the public-health math around herd immunity, the point at which enough people are immune that the virus cannot sustain chains of transmission. For measles that threshold is estimated at about 95 percent, higher than for almost any other vaccine-preventable disease. Communities with 90 percent coverage, which sounds excellent, remain vulnerable.

For an exposed adult, the timeline translates into practical steps. Count 21 days from the exposure; that is the period during which symptoms could appear. Watch for fever first, not rash. If symptoms begin, call ahead before visiting any clinic so that staff can prevent exposing waiting-room patients, and stay home from work through at least the fourth day after the rash appears.

What to do if you were exposed to measles as an adult

Exposure is a defined event in public-health terms: sharing a room, aircraft or other enclosed space with an infectious person, or entering that space within two hours of their leaving. Health departments notify exposed people when they can identify them, but adults often learn of exposure from a news alert about a flight or a store.

The first step is to establish immunity status using the four kinds of evidence described earlier. An adult with two documented doses, a positive titer or birth before 1957 is considered protected and generally needs only to watch for symptoms. Health departments may still ask health-care workers to monitor themselves more formally.

An adult without evidence of immunity has two time-sensitive options, and both belong to a clinician or public-health team rather than to self-management. The first is MMR vaccine given within 72 hours of exposure, which may prevent illness or lessen its severity and, if it fails to prevent infection, still leaves the person vaccinated for the future. The second is immune globulin, a preparation of antibodies collected from donated blood, given within six days of exposure. It is reserved for people who cannot receive a live vaccine, including pregnant women without evidence of immunity, infants and people with severely weakened immune systems, or for those who present after the 72-hour vaccine window has closed. Neither option guarantees protection; both shift the odds.

Exposed people without evidence of immunity are typically asked to stay away from work, school and public places from the fifth day after their first exposure through the twenty-first day after their last exposure, a quarantine period that reflects the incubation range. Health-care workers face stricter rules regardless of post-exposure treatment.

The mistake to avoid is walking into an urgent care or emergency department unannounced with a fever and a possible exposure history. A phone call first allows staff to arrange a separate entrance, an isolation room and masking, protecting the pregnant woman and the infant with cancer who might otherwise be sitting nearby. In the exposure window, courtesy and infection control are the same thing.

What the evidence actually says about measles immunity in adults

Not every statement in this article rests on the same footing. Sorting the claims by strength of evidence is the honest way to read them.

Strong evidence, from randomized trials and decades of surveillance. Two doses of MMR prevent about 97 percent of measles cases, and one dose about 93 percent. These figures come from controlled trials conducted during licensure and have been repeatedly confirmed in outbreak investigations comparing attack rates in vaccinated and unvaccinated people. The safety profile of MMR in adults, including the rarity of serious adverse events, rests on surveillance systems tracking hundreds of millions of doses.

Strong observational evidence. Vaccine-induced immunity is long-lasting. Cohort studies following vaccinated people for 20 to 30 years show persistent antibodies in the large majority, and the low rate of measles in fully vaccinated adults during recent outbreaks supports the conclusion that a routine booster is unnecessary. Natural infection confers lifelong immunity, a finding from serologic surveys of pre-vaccine-era adults. The complication rates cited for adults, including higher hospitalization and pneumonia risk, come from national surveillance data.

Moderate observational evidence. Immune amnesia after measles is supported by several well-conducted studies of children, including antibody profiling before and after infection, and by population-level data linking measles incidence to deaths from other infections. Direct studies in adults are limited, so the effect is inferred rather than measured.

Expert opinion and pragmatic guidance. The 1957 birth-year cutoff is a judgment call grounded in serologic data, not a trial result. The advice to revaccinate people who received the 1963–1967 killed vaccine reflects case series and mechanistic understanding rather than a controlled comparison. The 72-hour window for post-exposure MMR and the six-day window for immune globulin derive from older observational reports and immunologic reasoning; they are reasonable, widely adopted, and not precisely tested.

Where evidence is thin. Whether a low titer in a two-dose recipient predicts any real-world susceptibility remains uncertain. Cases of measles in twice-vaccinated adults exist and tend to be milder, but they are too rare to characterize precisely. That uncertainty is exactly why CDC advises against titer testing in people with good records: the test is more likely to worry than to inform.

Common myths about measles in adults, corrected

Outbreaks generate misinformation as reliably as they generate cases. These are the claims currently circulating most widely, and what mainstream evidence says about each.

“Adult immunity from childhood vaccination has worn off, so everyone needs a booster.” Antibody levels do decline slowly over decades, but immune memory persists, and surveillance shows that measles in fully vaccinated adults remains rare. CDC does not recommend a routine third dose. The people who genuinely need a dose are those who never completed the series or who received the inactivated vaccine of the mid-1960s.

“Vitamin A prevents measles.” WHO recommends vitamin A for children who already have measles, because deficiency worsens outcomes and supplementation reduces the risk of blindness and death in that setting. That is treatment of a complication, not prevention of infection. No study shows vitamin A prevents measles, and excessive intake can cause liver damage; cases of vitamin A toxicity have been reported during recent US outbreaks. Any use belongs under a clinician’s direction.

“Measles is a mild childhood illness.” In the United States, about one in five unvaccinated people who catch measles is hospitalized and one to three in 1,000 die. Adults face higher complication rates than school-age children. Before vaccination, measles killed an estimated 400 to 500 Americans every year.

“I had measles as a kid, so I’m covered.” True if the diagnosis was laboratory-confirmed. Many childhood rashes attributed to measles were something else, which is why a remembered illness does not count as evidence of immunity.

“Getting the vaccine when you’re already immune is dangerous.” Existing antibodies neutralize the vaccine virus. Giving MMR to an immune adult offers no benefit but causes no harm beyond ordinary injection-site soreness, which is why guidance allows vaccination without prior testing.

“Natural infection is better than the vaccine.” Natural infection does produce robust immunity. It also carries the complication rates above, plus immune amnesia. Two doses of MMR achieve comparable protection with none of those risks.

Who should not get the MMR vaccine, and who should wait

MMR is a live vaccine, and that single fact defines almost every exception. A weakened but living virus is safe for a healthy immune system and inappropriate for a few specific situations. The decision in every case below belongs to the treating clinician, who can weigh individual history against local risk.

Pregnancy. MMR is not given during pregnancy, and CDC advises avoiding pregnancy for at least four weeks after vaccination. This is precautionary; studies of women inadvertently vaccinated during pregnancy have not shown harm to the fetus, but live vaccines are withheld as a matter of principle. Women planning pregnancy who lack evidence of immunity are encouraged to sort out their status beforehand, and those found non-immune during prenatal screening are typically offered MMR after delivery.

Severely weakened immune systems. People with advanced HIV infection, those receiving chemotherapy or high-dose steroids, transplant recipients on immune-suppressing medicines and people with certain inherited immune deficiencies generally should not receive live vaccines. Their specialists make this call, and the same specialists arrange immune globulin if exposure occurs.

Severe allergic reaction to a previous dose or to a vaccine component. A history of anaphylaxis to MMR or to neomycin, an antibiotic present in trace amounts, is a contraindication. Egg allergy is not; the measles component is grown in chick-embryo cell culture, and studies have shown the vaccine is safe in people with egg allergy.

Reasons to postpone rather than avoid. Moderate or severe acute illness is a reason to wait until recovery. Recent receipt of blood products or immune globulin can blunt the vaccine response, so clinicians may delay vaccination for several months. A recent tuberculosis skin test interacts with MMR timing in ways that require scheduling rather than avoidance.

What is not a reason to avoid MMR. Breastfeeding, a mild cold, a family history of autism, and having a household member who is pregnant or immunocompromised are all compatible with vaccination. The vaccine virus is not transmitted from a vaccinated person to others.

Expected side effects in adults are mild: soreness at the injection site, a low fever a week or two later, and occasionally a faint rash or temporary joint stiffness, the last more common in adult women because of the rubella component.

When to see a doctor about measles in adults

Measles is a reportable disease, and any suspected case should involve a clinician and, through that clinician, the local health department. The advice below covers when to call, when to call urgently, and when to bypass the phone entirely.

Call your clinician promptly if you have been notified of a measles exposure and cannot document immunity; you develop fever with cough, runny nose and red eyes within 21 days of a known exposure or after travel to an area with active outbreaks; or you are pregnant, immunocompromised or caring for an infant and have any possible exposure. Call before arriving so staff can isolate you from other patients.

Seek urgent medical care if measles is suspected or confirmed and you notice any of the following, which CDC and Mayo Clinic identify as signs of complications:

• Difficulty breathing, rapid breathing, chest pain or a cough producing discolored sputum, which may indicate pneumonia
• Severe headache, stiff neck, confusion, unusual drowsiness or difficulty waking, which may indicate encephalitis
• Seizures
• Signs of dehydration such as very little urine, dizziness on standing or inability to keep fluids down
• Severe ear pain or discharge from the ear
• Fever that returns or climbs after the rash has begun to fade
• Eye pain, marked light sensitivity or vision changes beyond ordinary redness

In pregnancy, any suspected measles or exposure warrants same-day contact with the prenatal team, given the associations with miscarriage and premature birth.

After vaccination, mild soreness, low fever and a faint rash within two weeks are expected. Contact a clinician for high fever, hives, facial swelling, trouble breathing or any reaction that feels alarming; the last three, appearing within minutes to hours of the injection, are emergencies.

Every decision described in this article, including whether to test, whether to vaccinate, how to handle exposure and how to interpret a titer, rests with the clinician who knows your history. Guidance documents set the framework; the person in front of you fills in the details. If the paperwork is missing and the memories are fuzzy, that conversation is the place to start.

Frequently asked questions

What happens if an adult gets measles?

Adults tend to have more severe illness than school-age children. Expect a week or more of high fever, cough, red eyes and a spreading rash, with a higher chance of pneumonia, ear infection, diarrhea and, rarely, encephalitis. About one in five unvaccinated people is hospitalized. There is no antiviral treatment; care is supportive, so preventing infection through documented immunity matters more for adults than for almost any other group.

What are the symptoms of measles in adults?

Measles begins with fever, often above 104°F, cough, runny nose and red, watery eyes. Two to three days later small white Koplik spots may appear inside the cheeks. Three to five days after the first symptoms, a flat red rash starts at the hairline and spreads down the body. Adults usually report more severe fatigue, longer fevers and stronger light sensitivity than children, and the illness is frequently mistaken for influenza at first.

What does measles look like on adults?

The rash starts as flat red spots on the face and hairline, often with small bumps on top, then spreads downward over the trunk and limbs across about three days, merging into larger blotches. On darker skin it can look purple or dark brown and may be easier to feel than to see. The face-first, downward pattern combined with high fever, cough and red eyes distinguishes it from most other rashes.

When are you contagious after being exposed to measles?

You are not contagious immediately. Symptoms appear seven to fourteen days after exposure, sometimes up to 21, and you become infectious about four days before the rash appears, roughly when the fever and cough begin. Contagiousness continues until about four days after the rash emerges. Because the early stage looks like a cold, people often spread measles before anyone suspects it.

Do adults need an MMR booster?

Not routinely. CDC considers two documented MMR doses lifelong protection and does not recommend a third dose because time has passed. Adults who need a dose are those born in 1957 or later without any evidence of immunity, those with one dose who work in health care, travel internationally or attend college, and those vaccinated with the inactivated vaccine used between 1963 and 1967.

How do I find out if I am immune to measles?

Start with records: two documented MMR doses, a laboratory-confirmed past infection or US birth before 1957 all count as immunity. If none exists, a clinician can order a measles IgG titer, a blood test for protective antibodies. A positive result confirms immunity; a negative or equivocal result leads to vaccination. Alternatively, you can skip the test and receive MMR, since vaccinating an already-immune adult carries no added risk.

Is the measles vaccine for adults the same as the childhood one?

Yes. Adults receive the same MMR vaccine used in childhood, a live attenuated vaccine protecting against measles, mumps and rubella. The schedule differs: adults without evidence of immunity need one dose for ordinary risk or two doses at least 28 days apart for higher-risk settings. Side effects in adults are typically mild, with sore arm, low fever and occasionally temporary joint stiffness, the last more common in women because of the rubella component.

I had a measles titer and it came back negative, but I was vaccinated twice. Am I unprotected?

Probably not. Antibody levels can fall below a laboratory threshold in vaccinated people who still have immune memory capable of a rapid response. CDC advises that adults with two documented doses should not be considered susceptible on the basis of a low titer and do not need testing. Your clinician may still discuss an additional dose depending on your work and exposure risk, but the result alone does not mean you are vulnerable.

Can I get the MMR vaccine if I am pregnant or trying to conceive?

MMR is a live vaccine and is not given during pregnancy; CDC advises waiting at least four weeks after vaccination before trying to conceive. Studies of women inadvertently vaccinated in pregnancy have not shown fetal harm, so the rule is precautionary. Women found non-immune during prenatal screening are usually offered MMR after delivery. Timing and alternatives, including immune globulin after exposure, are decisions for the prenatal clinician.

Does vitamin A prevent measles?

No. WHO recommends vitamin A for children who already have measles, because it reduces the risk of blindness and death in that situation, particularly where deficiency is common. It does not prevent infection, and no study shows otherwise. Taking large amounts can damage the liver, and toxicity cases have been reported during recent outbreaks. Vaccination is the only proven prevention; any vitamin A use belongs under a clinician’s guidance.

References

• CDC – Measles Vaccination
• CDC – Measles Cases and Outbreaks
• NHS – Measles
• WHO – Measles Fact Sheet

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.